GLP-1 receptor agonists × glycemic control

TrialJAMA2016

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

Ildiko Lingvay et al.PubMed ↗Publisher ↗

What the trial testedas reported · 557 people · 2016

Not counted

Probably lowered glycemic control

−0.59percentage points−0.74 to −0.45

As reported

difference −0.59 %, 95% CI −0.74 to −0.45

Not counted

Probably lowered hypoglycaemia

−57%−70% to −39%

Bigger than 9 in 10 on the map

As reported

IRR 0.43, 95% CI 0.30–0.61

Two numbers in the abstract

the abstract, start to end

estimated treatment difference [ETD], -0.59% [95% CI, -0.74% to -0.45%]),

5.05 for glargine; estimated rate ratio, 0.43 [95% CI, 0.30 to

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.59−0.74 to −0.45
Hypoglycaemia
IRR 0.430.30–0.61
GLP-1 receptor agonistsInsulinGlycemic controlHypoglycaemia
1 / 3

117 papers cite itlatest 60 shown

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 26934259